

Global Speciality Generics Market Report and Forecast 2024-2032

Market Report | 2024-07-17 | 200 pages | EMR Inc.

AVAILABLE LICENSES:

- Single User License \$4999.00
- Five User License \$5999.00
- Corporate License \$6999.00

Report description:

Global Speciality Generics Market Report and Forecast 2024-2032

The global specialty generics market size was valued at USD 64.1 billion in 2023. It is expected to grow at a CAGR of 12.00% during the forecast period of 2024-2032, driven by the growing increased prevalence of chronic diseases requiring long-term medication. The market is experiencing robust growth and is expected to reach USD 177.7 billion by 2032.

Global Speciality Generics Market Analysis

Global specialty generics are a crucial segment of the pharmaceutical industry, encompassing medications that are chemically equivalent to brand-name drugs but differ in formulation, delivery method, or dosage strength. This market plays a significant role in providing affordable alternatives to expensive branded drugs, thereby enhancing accessibility to healthcare worldwide. Here's an analysis covering market drivers, challenges, and future opportunities:

Market Drivers:

- ☐ **Cost Containment:** Healthcare systems worldwide are under pressure to contain costs, driving the demand for affordable pharmaceutical alternatives. Specialty generics offer a cost-effective option compared to branded drugs, making them attractive to payers, healthcare providers, and patients.
- ☐ **Patent Expirations:** The expiry of patents on blockbuster drugs creates opportunities for specialty generics manufacturers to enter the market with their versions, capitalizing on the established demand for these medications.
- ☐ **Growing Aging Population:** As the global population ages, there is an increased prevalence of chronic diseases requiring long-term medication. Specialty generics targeting conditions such as cardiovascular diseases, diabetes, and cancer fulfill a critical need in managing these health issues.
- ☐ **Regulatory Support:** Regulatory agencies in various countries encourage the development and approval of generic medications to promote competition and improve access to healthcare. Expedited pathways for generic approvals streamline the market entry process for specialty generics.
- ☐ **Advancements in Drug Delivery Technologies:** Innovations in drug delivery technologies enable the development of novel formulations for specialty generics, offering improved efficacy, safety, and patient compliance. Controlled-release formulations, transdermal patches, and inhalable formulations are examples of such advancements.

Challenges:

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- ☐Complex Manufacturing Processes: Specialty generics often require sophisticated manufacturing processes due to their complex formulations or delivery mechanisms. Maintaining consistency and quality while adhering to regulatory standards poses challenges for manufacturers.
- ☐Regulatory Hurdles: Despite regulatory support, obtaining approvals for specialty generics can be challenging due to stringent requirements for demonstrating bioequivalence and safety. Differences in regulatory standards across regions add complexity to the approval process.
- ☐Intellectual Property Issues: Patent litigation and intellectual property disputes with originator companies can delay the market entry of specialty generics, affecting manufacturers' ability to capitalize on market opportunities.
- ☐Market Saturation: Some therapeutic areas within the specialty generics market may become saturated with multiple competitors, leading to pricing pressures and reduced profitability for manufacturers.
- ☐Supply Chain Disruptions: Global supply chain disruptions, such as those experienced during the COVID-19 pandemic, can impact the availability of raw materials, manufacturing capacity, and distribution networks, leading to supply shortages and price volatility.

Future Opportunities:

- ☐Biosimilars: The development of biosimilars, which are biologic drugs that are highly similar to reference products, presents a significant opportunity in the specialty generics market. As patents on biologic drugs expire, there is growing demand for biosimilar alternatives, particularly for high-cost biologics used in treating chronic diseases like rheumatoid arthritis and cancer.
- ☐Emerging Markets: Rapidly growing economies in regions such as Asia-Pacific, Latin America, and Africa present untapped opportunities for specialty generics manufacturers. Increasing healthcare expenditures, expanding access to healthcare, and rising disease burden drive demand for affordable medications in these markets.
- ☐Precision Medicine: Advancements in precision medicine and pharmacogenomics offer opportunities for developing personalized specialty generics tailored to individual patient profiles. Targeted therapies based on genetic markers or biomarkers can enhance efficacy and reduce adverse effects, improving patient outcomes.
- ☐Digital Health Integration: Integration of digital health technologies, such as telemedicine, remote patient monitoring, and digital therapeutics, creates opportunities for specialty generics manufacturers to differentiate their products and enhance patient engagement and adherence.
- ☐Collaboration and Partnerships: Collaborations between generic manufacturers, research institutions, and healthcare providers can facilitate innovation in specialty generics development, accelerate regulatory approvals, and expand market reach. Strategic partnerships for technology transfer, research collaborations, and market access initiatives can drive growth in the specialty generics market.

Global Specialty Generics Market Trends

Market trends in the global specialty generics sector are shaped by various factors, including technological advancements, regulatory changes, healthcare policies, and shifting consumer preferences. Here are some key market trends:

- ☐Biosimilars Adoption: The adoption of biosimilars continues to grow, driven by the expiration of patents on biologic drugs and efforts to reduce healthcare costs. Governments and healthcare systems are increasingly incentivizing the use of biosimilars to improve access to expensive biologic therapies, creating opportunities for specialty generics manufacturers.
- ☐Emerging Markets Growth: Emerging markets, particularly in Asia-Pacific, Latin America, and Africa, are witnessing rapid growth in demand for specialty generics due to expanding healthcare infrastructure, rising disposable incomes, and increasing prevalence of chronic diseases. Specialty generics manufacturers are increasingly focusing on these markets to capitalize on growth opportunities.
- ☐Digital Health Integration: Integration of digital health technologies such as telemedicine, remote patient monitoring, and electronic health records is reshaping the specialty generics landscape. Manufacturers are exploring opportunities to leverage digital health solutions to enhance patient engagement, adherence, and outcomes.
- ☐Personalized Medicine: Advances in precision medicine and pharmacogenomics are driving the development of personalized specialty generics tailored to individual patient profiles. Targeted therapies based on genetic markers or biomarkers offer the potential to improve treatment efficacy and safety, driving demand for personalized specialty generics.

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- Regulatory Harmonization: Efforts to harmonize regulatory standards across regions are facilitating the global development and approval of specialty generics. Harmonized regulatory pathways streamline the approval process, reduce development costs, and enable manufacturers to access multiple markets more efficiently.
- Vertical Integration: Some specialty generics manufacturers are pursuing vertical integration strategies to enhance their competitiveness and market presence. Vertical integration involves controlling multiple stages of the pharmaceutical value chain, including drug development, manufacturing, distribution, and sales, to optimize efficiency and capture greater value.
- Focus on Specialty Therapeutic Areas: Specialty generics manufacturers are increasingly focusing on therapeutic areas with high unmet medical needs and significant market potential, such as oncology, autoimmune diseases, central nervous system disorders, and rare diseases. Developing specialty generics for these areas requires specialized expertise and resources but offers attractive growth opportunities.
- Sustainability and Environmental Awareness: There is growing awareness of the environmental impact of pharmaceutical manufacturing and distribution processes. Specialty generics manufacturers are exploring sustainable practices, such as reducing carbon emissions, minimizing waste generation, and optimizing resource utilization, to align with evolving environmental regulations and consumer preferences.
- Supply Chain Resilience: The COVID-19 pandemic highlighted vulnerabilities in global supply chains, prompting specialty generics manufacturers to reassess their supply chain strategies. Companies are investing in building more resilient and diversified supply chains, with increased emphasis on local sourcing, inventory management, and risk mitigation measures.
- Patient-Centric Approaches: Patient-centricity is increasingly becoming a priority for specialty generics manufacturers, with a focus on understanding and addressing patient needs, preferences, and experiences. Manufacturers are investing in patient support programs, educational initiatives, and digital tools to empower patients and improve medication adherence and health outcomes.

Global Specialty Generics Market Segmentation

Market Breakup by Type

- Injectables
- Oral drugs
- Others

The global pharmaceutical market, segmented by type into injectables, oral drugs, and others, exhibits promising growth prospects driven by diverse market drivers. Injectable drugs are fueled by the rising prevalence of chronic diseases, technological advancements, and the demand for targeted therapies, with future growth expected from the increasing adoption of biologics and biosimilars. Oral drugs benefit from the convenience of administration, expanding treatment options, and the aging population, poised for growth in emerging markets and therapeutic areas such as oncology and cardiovascular diseases. Other segments encompass innovative drug delivery systems, including transdermal patches and inhalation therapies, contributing to market expansion through enhanced efficacy, patient compliance, and therapeutic outcomes.

Market Breakup by Applications

- Oncology
- Inflammatory conditions
- Multiple sclerosis
- Hepatitis C
- Others

The pharmaceutical market, categorized by applications into oncology, inflammatory conditions, multiple sclerosis, hepatitis C, and others, showcases robust growth potential bolstered by key market drivers. Oncology applications thrive due to increasing cancer incidence, advancements in targeted therapies, and personalized medicine approaches, with future growth anticipated from emerging markets and innovative treatment modalities. Inflammatory conditions benefit from the rising prevalence of

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

autoimmune diseases, biologic drug advancements, and healthcare infrastructure developments, driving expansion particularly in rheumatoid arthritis and inflammatory bowel disease treatments. Multiple sclerosis treatments grow alongside improved diagnostic capabilities, expanding patient populations, and ongoing research into disease-modifying therapies, poised for significant growth in the forecast period. Hepatitis C therapeutics flourish due to improved treatment efficacy, increased screening efforts, and government initiatives to eradicate the disease, with potential for further expansion in underserved regions. Other applications encompass a range of therapeutic areas, including cardiovascular diseases, diabetes, and rare diseases, contributing to market growth through diversified treatment options and evolving patient needs.

Market Breakup by End User

- Specialty pharmacy
- Retail pharmacy
- Hospital pharmacy

Segmented by end users into specialty pharmacy, retail pharmacy, and hospital pharmacy, the pharmaceutical market demonstrates promising growth prospects underpinned by various market drivers. Specialty pharmacy services witness expansion due to increasing demand for complex therapies, personalized medicine, and specialty drugs, with future growth expected from rising healthcare expenditures and the prevalence of chronic diseases. Retail pharmacy outlets benefit from convenience, accessibility, and over-the-counter medication sales, poised for further growth fueled by expanding patient populations and healthcare awareness. Hospital pharmacies thrive on the demand for acute care services, inpatient treatments, and specialized medications, with future growth anticipated from healthcare infrastructure developments and advancements in hospital-based treatments.

Market Breakup by Region

- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa

The pharmaceutical market, segmented by region into North America, Europe, Asia Pacific, Latin America, and Middle East and Africa, presents significant growth opportunities driven by diverse market dynamics. North America leads with advanced healthcare infrastructure, high pharmaceutical expenditure, and strong regulatory frameworks, poised for further growth propelled by increasing demand for specialty drugs and biologics. Europe benefits from extensive market access, favorable reimbursement policies, and robust pharmaceutical research, with future growth anticipated from biosimilar adoption and healthcare digitization initiatives. Asia Pacific showcases rapid market expansion fueled by rising healthcare investments, expanding middle-class populations, and increasing prevalence of chronic diseases, with China and India emerging as key growth markets. Latin America demonstrates growth potential driven by improving healthcare access, expanding pharmaceutical markets, and government initiatives to enhance healthcare infrastructure and affordability. Middle East and Africa present opportunities for market growth spurred by increasing healthcare investments, rising disease burden, and government efforts to improve healthcare access and quality, with future growth expected from expanding pharmaceutical manufacturing capabilities and partnerships with global pharmaceutical companies.

Global Specialty Generics Market Competitive Landscape

The competitive landscape of the pharmaceutical market is characterized by intense competition and strategic activities among key players. Viatris Inc., formed through a merger, stands as a major player alongside Novartis AG, Teva Pharmaceutical Industries Ltd., and Bausch Health Companies Inc., engaged in extensive research initiatives and product introductions. Mallinckrodt and Endo Inc. focus on specialty pharmaceuticals, while STADA Arzneimittel AG and Sun Pharmaceutical Industries Ltd. expand through mergers and acquisitions. Apotex Inc. and Dr. Reddy's Laboratories Ltd. strengthen their market presence

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

through partnerships and diversified product portfolios. Hikma Pharmaceuticals PLC and Lupin emphasize geographical expansion and innovative therapies, while Amneal Pharmaceuticals LLC. focuses on generic drug development and strategic collaborations. Mergers, acquisitions, research initiatives, product introductions, and partnerships are common market activities among these key players, driving competition and innovation in the pharmaceutical industry.

Key Questions Answered in the Report

- What is the current and future performance of the specialty generics market?
- What are the main challenges facing the specialty generics market?
- What are the key drivers of the specialty generics market?
- What emerging trends are shaping the future of the specialty generics market?
- What factors are driving growth in oncology applications within the pharmaceutical market?
- How do precision medicine and pharmacogenomics enhance the development of personalised specialty generics?
- How is the adoption of biosimilars shaping opportunities for specialty generics manufacturers?
- What are the common strategies used by key players in the specialty generics market?

Key Benefits for Stakeholders

?□The industry report offers a comprehensive quantitative analysis of various market segments, historical and current market trends, market forecasts, and dynamics of the global specialty generics market from 2017-2032.

?□The research report provides the latest information on the market drivers, challenges, and opportunities in the specialty generics market.

?□The study maps the leading, as well as the fastest-growing, regional markets. It further enables stakeholders to identify the key country-level markets within each region.

?□Porter's five forces analysis assists stakeholders in assessing the impact of new entrants, competitive rivalry, supplier power, buyer power, and the threat of substitution. It helps stakeholders to analyze the level of competition within the specialty generics industry and its attractiveness.

?□The competitive landscape allows stakeholders to understand their competitive environment and provides insight into the current positions of key players in the market.

Table of Contents:

- 1 Preface
- 2 Report Coverage - Key Segmentation and Scope
- 3 Report Description
 - 3.1 Market Definition and Outlook
 - 3.2 Properties and Applications
 - 3.3 Market Analysis
 - 3.4 Key Players
- 4 Key Assumptions
- 5 Executive Summary
 - 5.1 Overview
 - 5.2 Key Drivers
 - 5.3 Key Developments
 - 5.4 Competitive Structure
 - 5.5 Key Industrial Trends
- 6 Snapshot
 - 6.1 Global
 - 6.2 Regional
- 7 Opportunities and Challenges in the Market
- 8 Global Speciality Generics Market Analysis
 - 8.1 Key Industry Highlights

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 8.2 Global Speciality Generics Historical Market (2018-2023)
- 8.3 Global Speciality Generics Market Forecast (2024-2032)
- 8.4 Global Speciality Generics Market by Route of Administration
 - 8.4.1 Injectable
 - 8.4.1.1 Historical Trend (2018-2023)
 - 8.4.1.2 Forecast Trend (2024-2032)
 - 8.4.2 Oral
 - 8.4.2.1 Historical Trend (2018-2023)
 - 8.4.2.2 Forecast Trend (2024-2032)
 - 8.4.3 Others
- 8.5 Global Speciality Generics Market by Indication
 - 8.5.1 Oncology
 - 8.5.1.1 Historical Trend (2018-2023)
 - 8.5.1.2 Forecast Trend (2024-2032)
 - 8.5.2 Autoimmune Diseases
 - 8.5.2.1 Historical Trend (2018-2023)
 - 8.5.2.2 Forecast Trend (2024-2032)
 - 8.5.3 Infectious Diseases
 - 8.5.3.1 Historical Trend (2018-2023)
 - 8.5.3.2 Forecast Trend (2024-2032)
 - 8.5.4 Others
- 8.6 Global Speciality Generics Market by Distribution Channel
 - 8.6.1 Retail Pharmacies
 - 8.6.1.1 Historical Trend (2018-2023)
 - 8.6.1.2 Forecast Trend (2024-2032)
 - 8.6.2 Speciality Pharmacies
 - 8.6.2.1 Historical Trend (2018-2023)
 - 8.6.2.2 Forecast Trend (2024-2032)
 - 8.6.3 Hospital Pharmacies
 - 8.6.3.1 Historical Trend (2018-2023)
 - 8.6.3.2 Forecast Trend (2024-2032)
 - 8.6.4 Others
- 8.7 Global Speciality Generics Market by Region
 - 8.7.1 North America
 - 8.7.1.1 Historical Trend (2018-2023)
 - 8.7.1.2 Forecast Trend (2024-2032)
 - 8.7.2 Europe
 - 8.7.2.1 Historical Trend (2018-2023)
 - 8.7.2.2 Forecast Trend (2024-2032)
 - 8.7.3 Asia Pacific
 - 8.7.3.1 Historical Trend (2018-2023)
 - 8.7.3.2 Forecast Trend (2024-2032)
 - 8.7.4 Latin America
 - 8.7.4.1 Historical Trend (2018-2023)
 - 8.7.4.2 Forecast Trend (2024-2032)
 - 8.7.5 Middle East and Africa
 - 8.7.5.1 Historical Trend (2018-2023)

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 8.7.5.2 Forecast Trend (2024-2032)
- 9 North America Speciality Generics Market Analysis
 - 9.1 United States of America
 - 9.1.1 Historical Trend (2018-2023)
 - 9.1.2 Forecast Trend (2024-2032)
 - 9.2 Canada
 - 9.2.1 Historical Trend (2018-2023)
 - 9.2.2 Forecast Trend (2024-2032)
- 10 Europe Speciality Generics Market Analysis
 - 10.1 United Kingdom
 - 10.1.1 Historical Trend (2018-2023)
 - 10.1.2 Forecast Trend (2024-2032)
 - 10.2 Germany
 - 10.2.1 Historical Trend (2018-2023)
 - 10.2.2 Forecast Trend (2024-2032)
 - 10.3 France
 - 10.3.1 Historical Trend (2018-2023)
 - 10.3.2 Forecast Trend (2024-2032)
 - 10.4 Italy
 - 10.4.1 Historical Trend (2018-2023)
 - 10.4.2 Forecast Trend (2024-2032)
 - 10.5 Others
- 11 Asia Pacific Speciality Generics Market Analysis
 - 11.1 China
 - 11.1.1 Historical Trend (2018-2023)
 - 11.1.2 Forecast Trend (2024-2032)
 - 11.2 Japan
 - 11.2.1 Historical Trend (2018-2023)
 - 11.2.2 Forecast Trend (2024-2032)
 - 11.3 India
 - 11.3.1 Historical Trend (2018-2023)
 - 11.3.2 Forecast Trend (2024-2032)
 - 11.4 ASEAN
 - 11.4.1 Historical Trend (2018-2023)
 - 11.4.2 Forecast Trend (2024-2032)
 - 11.5 Australia
 - 11.5.1 Historical Trend (2018-2023)
 - 11.5.2 Forecast Trend (2024-2032)
 - 11.6 Others
- 12 Latin America Speciality Generics Market Analysis
 - 12.1 Brazil
 - 12.1.1 Historical Trend (2018-2023)
 - 12.1.2 Forecast Trend (2024-2032)
 - 12.2 Argentina
 - 12.2.1 Historical Trend (2018-2023)
 - 12.2.2 Forecast Trend (2024-2032)
 - 12.3 Mexico

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 12.3.1 Historical Trend (2018-2023)
 - 12.3.2 Forecast Trend (2024-2032)
- 12.4 Others
- 13 Middle East and Africa Speciality Generics Market Analysis
 - 13.1 Saudi Arabia
 - 13.1.1 Historical Trend (2018-2023)
 - 13.1.2 Forecast Trend (2024-2032)
 - 13.2 United Arab Emirates
 - 13.2.1 Historical Trend (2018-2023)
 - 13.2.2 Forecast Trend (2024-2032)
 - 13.3 Nigeria
 - 13.3.1 Historical Trend (2018-2023)
 - 13.3.2 Forecast Trend (2024-2032)
 - 13.4 South Africa
 - 13.4.1 Historical Trend (2018-2023)
 - 13.4.2 Forecast Trend (2024-2032)
 - 13.5 Others
- 14 Market Dynamics
 - 14.1 SWOT Analysis
 - 14.1.1 Strengths
 - 14.1.2 Weaknesses
 - 14.1.3 Opportunities
 - 14.1.4 Threats
 - 14.2 Porter's Five Forces Analysis
 - 14.2.1 Supplier's Power
 - 14.2.2 Buyer's Power
 - 14.2.3 Threat of New Entrants
 - 14.2.4 Degree of Rivalry
 - 14.2.5 Threat of Substitutes
 - 14.3 Key Indicators for Demand
 - 14.4 Key Indicators for Price
- 15 Value Chain Analysis
- 16 Competitive Landscape
 - 16.1 Market Structure
 - 16.2 Company Profiles
 - 16.2.1 Teva Pharmaceutical Industries Ltd.
 - 16.2.1.1 Company Overview
 - 16.2.1.2 Product Portfolio
 - 16.2.1.3 Demographic Reach and Achievements
 - 16.2.1.4 Financial Summary
 - 16.2.1.5 Certifications
 - 16.2.2 Mylan N.V.
 - 16.2.2.1 Company Overview
 - 16.2.2.2 Product Portfolio
 - 16.2.2.3 Demographic Reach and Achievements
 - 16.2.2.4 Financial Summary
 - 16.2.2.5 Certifications

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 16.2.3 Mallinckrodt plc
 - 16.2.3.1 Company Overview
 - 16.2.3.2 Product Portfolio
 - 16.2.3.3 Demographic Reach and Achievements
 - 16.2.3.4 Financial Summary
 - 16.2.3.5 Certifications
- 16.2.4 Pfizer, Inc.
 - 16.2.4.1 Company Overview
 - 16.2.4.2 Product Portfolio
 - 16.2.4.3 Demographic Reach and Achievements
 - 16.2.4.4 Financial Summary
 - 16.2.4.5 Certifications
- 16.2.5 Sun Pharmaceutical Industries Ltd
 - 16.2.5.1 Company Overview
 - 16.2.5.2 Product Portfolio
 - 16.2.5.3 Demographic Reach and Achievements
 - 16.2.5.4 Financial Summary
 - 16.2.5.5 Certifications
- 16.2.6 Apotex Inc.
 - 16.2.6.1 Company Overview
 - 16.2.6.2 Product Portfolio
 - 16.2.6.3 Demographic Reach and Achievements
 - 16.2.6.4 Financial Summary
 - 16.2.6.5 Certifications
- 16.2.7 Others
- 17 Key Trends and Developments in the Market

List of Key Figures and Tables

1. Global Speciality Generics Market: Key Industry Highlights, 2018 and 2032
2. Global Speciality Generics Historical Market: Breakup by Route of Administration (USD Billion), 2018-2023
3. Global Speciality Generics Market Forecast: Breakup by Route of Administration (USD Billion), 2024-2032
4. Global Speciality Generics Historical Market: Breakup by Indication (USD Billion), 2018-2023
5. Global Speciality Generics Market Forecast: Breakup by Indication (USD Billion), 2024-2032
6. Global Speciality Generics Historical Market: Breakup by Distribution Channel (USD Billion), 2018-2023
7. Global Speciality Generics Market Forecast: Breakup by Distribution Channel (USD Billion), 2024-2032
8. Global Speciality Generics Historical Market: Breakup by Region (USD Billion), 2018-2023
9. Global Speciality Generics Market Forecast: Breakup by Region (USD Billion), 2024-2032
10. North America Speciality Generics Historical Market: Breakup by Country (USD Billion), 2018-2023
11. North America Speciality Generics Market Forecast: Breakup by Country (USD Billion), 2024-2032
12. Europe Speciality Generics Historical Market: Breakup by Country (USD Billion), 2018-2023
13. Europe Speciality Generics Market Forecast: Breakup by Country (USD Billion), 2024-2032
14. Asia Pacific Speciality Generics Historical Market: Breakup by Country (USD Billion), 2018-2023
15. Asia Pacific Speciality Generics Market Forecast: Breakup by Country (USD Billion), 2024-2032
16. Latin America Speciality Generics Historical Market: Breakup by Country (USD Billion), 2018-2023
17. Latin America Speciality Generics Market Forecast: Breakup by Country (USD Billion), 2024-2032
18. Middle East and Africa Speciality Generics Historical Market: Breakup by Country (USD Billion), 2018-2023

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

19. Middle East and Africa Speciality Generics Forecast: Breakup by Country (USD Billion), 2024-2032
20. Global Speciality Generics Market Structure

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Global Speciality Generics Market Report and Forecast 2024-2032

Market Report | 2024-07-17 | 200 pages | EMR Inc.

To place an Order with Scotts International:

- ☐ - Print this form
- ☐ - Complete the relevant blank fields and sign
- ☐ - Send as a scanned email to support@scotts-international.com

ORDER FORM:

Select license	License	Price
	Single User License	\$4999.00
	Five User License	\$5999.00
	Corporate License	\$6999.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

☐ ** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2025-05-04"/>
		Signature	<input type="text"/>

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com